drugset / Trial / NCT00002418
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
Phase 2
Terminated
25 enrolled
Bristol-Myers Squibb
Boehringer Ingelheim · collabTriangle Pharmaceuticals · collab
Treatment
Summary
The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to respond to protease inhibitors (PIs). The drug combination will contain didanosine (ddI) plus stavudine (d4T) plus nevirapine (NVP) plus MKC-442. Hydroxyurea (HU) may be added.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Didanosine | Small molecule | — | — |
| Subject | Emivirine | Small molecule | — | — |
| Subject | Hydroxyurea | Other / unclassified | — | — |
| Subject | Nevirapine | Small molecule | — | — |
| Subject | Stavudine | Other / unclassified | — | — |